Sinovac Biotech Co., Ltd

This Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis in infants aged 6 to 11 months. About 1,040 healthy babies will receive either the experimental vaccine or a licensed comparator. Researchers will check immun…

This early-stage trial will test the safety of a new RSV mRNA vaccine in 60 healthy adults aged 18 and older. Participants will receive either a low dose, high dose, or a placebo (saline) shot. The study aims to see if the vaccine causes any side effects, paving the way for large…

This phase 3 trial tests a new meningococcal conjugate vaccine in 660 healthy children aged 2 to 6 years. The vaccine targets four strains of the bacteria that cause meningitis and bloodstream infections. Participants receive one shot and provide blood samples to measure immune r…

This study tests a new vaccine designed to prevent hand, foot, and mouth disease (HFMD) and herpangina in children aged 6 months to 5 years. About 6,000 healthy children will receive either the vaccine or a placebo to see if it safely protects against four common virus types that…

This study tests a new vaccine to protect young children (12-23 months old) against four types of meningococcal bacteria that can cause meningitis. About 1,040 toddlers will receive either the new vaccine or an existing one to see if the new vaccine is as safe and effective. The …

This study tests a new vaccine to protect babies aged 3 to 5 months against meningitis caused by four types of bacteria (A, C, Y, W135). About 880 infants will receive either the new vaccine or an existing one to compare safety and immune response. The goal is to see if the new v…

This phase 3 trial tests whether three different batches of a rabies vaccine produce the same immune response and are safe. It involves 912 healthy adults aged 18-45. The vaccine is given after a potential rabies exposure to prevent the disease.